

			Quarter ended		Year ended	
SI. No.	Particulars	31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Segment wise revenue and results:					
	Segment revenue:					
	a) Pharmaceutical Services and Active ingredients	7,699	6,785	6,850	27,484	27,458
	b) Global Generics	27,836	30,105	29,138	114,014	115,409
	c) Proprietary Products	848	2,137	552	4,245	2,363
	d) Others	414	382	451	1,777	1,760
	Total	36,797	39,409	36,991	147,520	146,990
	Less: Inter-segment revenues	1,448	1,349	1,449	5,492	6,181
	Net revenue from operations	35,349	38,060	35,542	142,028	140,809
2	Segment results:					
	Gross profit from each segment					
	a) Pharmaceutical Services and Active Ingredients	1,510	1,296	541	4,446	4,473
	b) Global Generics	16,506	17,912	17,024	67,190	71,079
	c) Proprietary Products	726	2,022	410	3,799	1,951
	d) Others	153	181	207	869	853
	Total	18,895	21,411	18,182	76,304	78,356
	Less: Selling and other un-allocable expenditure, net of other income	15,147	15,466	14,993	61,963	63,703
	Total profit before tax	3,748	5,945	3,189	14,341	14,653